An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055 · tracked via the Priya Life Science USA tracker

Sponsor

Vanda Pharmaceuticals

Phase

Phase 2

Started

2025-10

Last updated

2025-09-17

Condition(s) studied

Dry Eye

Investigational drug(s) / intervention(s)

VSJ-110Placebo

VSJ-110: ophthalmic solution

Placebo: ophthalmic solution

Study summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.

Primary outcome measure(s)

Corneal Staining — Measured over an 8-week treatment period
Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.

Trial sites (5)

Facility	City	Region	Status
Vanda Investigational Site	Newport Beach	California	Recruiting
Vanda Investigational Site	Andover	Massachusetts	Not Yet Recruiting
Vanda Investigational Site	Shelby	North Carolina	Not Yet Recruiting
Vanda Investigational Site	Memphis	Tennessee	Recruiting
Vanda Investigational Site	Lynchburg	Virginia	Not Yet Recruiting

More Vanda Pharmaceuticals trials in the USA

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

Patient Registry of Blind Subjects With Sleep-related Problems Recruiting

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Active, not recruiting

Other trials for the same condition

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. Active, not recruiting

The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07179055 on ClinicalTrials.gov ↗ ← All trials in the USA